Creative Biolabs explores new treatment options in immuno-oncology
Category : #Health  By- Puja More  Date: 2020-11-05
  • share
  • Twitter
  • Facebook
  • LinkedIn
Creative Biolabs explores new treatment options in immuno-oncology

Creative Biolabs Inc., the U.S-based life-science firm offering biotech products and services for early drug discovery and development, has reportedly announced that it is exploring new fields in precision medicine to develop novel treatments for life-threatening diseases like cancer.

From gene to bio-therapeutics, the life science firm has already introduced integrated protein and therapeutic antibody platforms. These platforms cover the complete pipeline that is composed of biologics testing, discovery, preclinical testing, development, IND regulatory service, cGMP manufacturing, and modality.

Biological assays are able to give out complete information about drugs' biological activities by observing their impacts on living animals or tissues. It can also detect biohazards, providing a top-quality evaluation of mixtures, evaluates environmental impact, and assess the safety of new technology and facilities.

Creative Biolabs has all-inclusive biologics testing services (structure characterization, immunoassay, post-translational modification, biomarker development, etc.) that are offered by the veterans in oncology immunotherapy, covering the complete drug development cycle and guaranteed to be in accordance with GMP regulations.

According to sources familiar with the knowledge of matter, complete workflow follows the authoritative rules and regulations (EMA, FDA). Moreover, this enables healthcare organizations to perform all-around testing, including microbiology, microbiology, and molecular biology.

The Shirley-based firm developed numerous development platforms to advance the research in immunotherapy in crucial stages, which are aided by top-notch GMP (Good Manufacturing Practice) manufacturing facilities.

The almighty service portfolio comprises cell banking, cell line development, cell link characterization, purification development, cell culture process development, formulation development, and so on. Among which the cell line development is popular among healthcare companies requiring a stable cell line that is outstanding in developing recombinant protein and monoclonal antibody. Moreover, the company can handle process development, cell line construction, cell analysis, cell banking, and other corresponding projects.

Source credit - https://menafn.com/1101074033/Creative-Biolabs-Immuno-Oncology-Programs-Enable-Efficient-Development-of-Innovative-Therapeutic-Candidates

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Puja More    

Puja More

Puja More holds a graduate degree in Computer Science from the University of Pune. Nurturing her passion of playing with words however, Puja undertook content writing as a career path and boasts of rich experience in content production, copywriting, and digital market...

Read More

Most Read

Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists
Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists
By- Puja More  Date: 2020-12-03

Biohaven Pharmaceutical Holding Company and Sosei Group Corporation have signed a collaboration and licensing agreement under which the form...

Cerus receives FDA nod for INTERCEPT Blood System for Cryoprecipitation
Cerus receives FDA nod for INTERCEPT Blood System for Cryoprecipitation
By- Madhura Dethe  Date: 2020-12-02

Adding to yet other initiatives and accomplishments in the medical fraternity, a California-based pathogen-protected blood component develop...

Nigeria set to commence installation of 5Mn solar home power systems
Nigeria set to commence installation of 5Mn solar home power systems
By- Puja More  Date: 2020-12-01

The first phase of installation is expected to be commenced in December 2020 nationwide. The Federal Government of Nigeria has recently sta...

Ascentage partners with U-M to attain license for a MDM2 degrader
Ascentage partners with U-M to attain license for a MDM2 degrader
By- Puja More  Date: 2020-11-30

Acquisitions, collaborations, and mergers have become a common practice in the medical and biotechnology sector in recent years. Speaking of...

Our Conrtributor

Apple launches ‘AirPods Max’, its first over-ear headphones at $550

Apple launches ‘AirPods Max’, its first over-ear headphones at $550

By- Puja More

Technology giant- Apple Inc. has recently unveiled the ‘AirPods Max’, active noise-cance...

Zydus receives DGCI approval for Phase-1 clinical trial of ZYIL1

Zydus receives DGCI approval for Phase-1 clinical trial of ZYIL1

By- Puja More

ZYIL1 stands out to be a novel oral small molecule NLRP3 inhibitor candidate which is expected to be...

Gupshup to better business communications, launches GIP for the same

Gupshup to better business communications, launches GIP for the same

By- Puja More

Messaging services company, Gupshup has reportedly launched an all-new IP-based messaging channel wi...